Mayne Pharma Group Limited (ASX: MYX), a specialty pharmaceutical company, has commercially launched a generic version of ORTHO-CEPT (desogestrel and ethinyl estradiol 0.15mg/0.03mg) tablets in the United States, it was reported on Thursday.
The product is the fourth oral contraceptive introduced in 2021 after launching generic versions of LOESTRIN 24 FE, ORTHO CYCLEN and ORTHO TRI-CYCLEN.
Mayne Pharma's CEO, Scott Richards, said, 'We are very pleased to expand our Women's Health portfolio, which now covers ~80 percent of Obstetrician/Gynaecologist oral contraceptive prescription volumes [1] and includes 24 marketed branded generic contraceptives. Mayne Pharma is committed to helping meet the needs of women in the US by providing cost effective, high-quality and novel contraceptive options. The four new products launched this year were sourced from the strategic partnership with Novast Laboratories.'
[1] IQVIA, MAT Sales and NSP Units for brand and generic equivalents, January 2021
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US